Save the date for the Sarcoma Foundation of America’s 20th annual fundraising gala, Stand Up to Sarcoma, which will be held on September 28, 2022, at the Edison Ballroom in New York City. Join us as we gather to honor those who are making a difference in the sarcoma community.

Stand Up to Sarcoma is a signature event of the Sarcoma Foundation of America (SFA), highlighting outstanding sarcoma advocates with the Courage Award. SFA will also be honoring a researcher or doctor investigating groundbreaking research with the Nobility in Science Award and recognizing an organization or person in recognition of the honoree’s efforts to advance the care and treatment of sarcoma, bringing hope to patients and survivors with the Vision of Hope Award.  The Compassionate Care Award recognizes a patient/nurse navigator (clinical/nurse, community health worker, social worker in the role of a navigator) for his or her outstanding contributions to patient care, support or education.  These international awards are the highest honor SFA bestows and are awarded each year at the Stand Up to Sarcoma Gala.

Along with these recognitions, this gala serves as a signature event of the organization in two important ways:

  1. It is a primary fundraising event for the organization; It is the premier event that best highlights the mission of the Sarcoma Foundation of America.
  2. Net proceeds from the event will benefit the 2023 research and patient education programs; Funding sarcoma research grants and educating patients about novel therapies and empowering them to be better advocates for their care.

SFA relies on the devotion and support of donors and friends to continue working to find new and better therapies, and ultimately the cure, for sarcoma. Your support will aide in the effort to fund research and provide resources for the sarcoma community.

We hope you will join the SFA community to honor outstanding and inspirational leaders who proudly represent the important work of SFA while raising money for much needed research.

LOCATION: Edison Ballroom, New York, NY

DATE:  Wednesday, September 28, 2022

TIME:  6-10 PM EDT

.

.

Dinner Event | Cocktail Attire

HOST: Caroline Aaron
ENTERTAINMENT:  The Doo Wop Project

Caroline Aaron

SAG Award winning actress Caroline Aaron currently stars as ‘Shirley Maisel’ opposite Rachel Brosnahan, Tony Shaloub, and Alex Borstein in season 4 of Amazon/Amy Sherman-Palladino’s Golden Globe, Emmy Award, and Critics’ Choice Award-winning comedy series “The Marvelous Mrs. Maisel.The versatile and acclaimed actress got her roots in Richmond, Virginia, the daughter of a prominent civil rights activist. After studying performing arts at American University in Washington, D.C., she moved to NY and debuted on Broadway in Robert Altman’s Come Back to the Five and Dime, Jimmy Dean, Jimmy Dean. The following season, Caroline starred in the back to back Broadway smashes The Iceman Cometh, and I Hate Hamlet, cementing her as the big apple’s most stirring acclaim to fame. On the big screen, Caroline has built her acting career as a loveable and unforgettable character actress. She has appeared in over a hundred box office hits, including Hello, My Name is Doris, 21 & 22 Jump Street, Beyond The Sea, Just Like Heaven, Nancy Drew, Sleepless in Seattle, Edward Scissorhands, and many more. Her television work includes “Grey’s Anatomy,” “Modern Family,” “Sex and The City,” “Curb Your Enthusiasm,” “Transparent,” as well as “Episodes,” “The Good Fight,” and her latest Israeli comedy “Chanshi,” which she just wrapped filming in Israel. Aaron also appeared on a much-discussed episode of the hit CBS comedy series “Ghosts” earlier this year. When she is not on the set of “The Marvelous Mrs. Maisel”, Caroline enjoys catching up with her two children, playwriting, and producing her podcast series, Angst and Daisies.

 

The Vision of Hope Award is presented to a person or organization through public or private actions has resulted in the advancement of care, treatment or awareness for sarcoma patients. The honoree impacts the lives of sarcoma patients and survivors providing them hope for a better future and whose achievements provide increased hope for better patient outcomes.

Adaptimmune is driven by a mission to transform the lives of people with cancer by designing and delivering cell therapies. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cell receptors (TCRs) to target and destroy cancer, including solid tumors.

 

The Company is preparing for its first biologics license application (BLA) submission of the first-ever engineered TCR T-cell therapy for solid cancer tumors. If approved, this TCR therapy will be used to treat patients with synovial sarcoma, a rare cancer for which there is a high unmet medical need.

 

Adaptimmune has been purposefully built as an integrated cell therapy company, owning each stage of the development, manufacturing, and commercialization of its SPEAR T-cell therapies for cancer, setting it apart from other biotechnology companies in the field. 

The Nobility in Science Award is given annually to a deserving visionary, who has been a leading sarcoma surgeon and researcher and has taken on an integral role in advancing drug development for sarcoma patients. Awardees receiving this honor have contributed in a significant way to the advancement of, care, treatment, for sarcoma patients. This award is given to an outstanding scientist who is dedicated to the advancement of knowledge of sarcoma and works tirelessly to find new and innovative approaches for treating this rare cancer.

Crystal Mackall, MD

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine, Stanford University

 

Crystal L Mackall MD is the Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and Internal Medicine at Stanford University. She is the Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology Program and Director of the Parker Institute for Cancer Immunotherapy at Stanford. During a 27 year tenure culminating as Chief of the Pediatric Oncology Branch, NCI, and now at Stanford, she leads an internationally recognized an oncology research program focusing on immunology that spans basic, translational and clinical research. Her work creates new knowledge and simultaneously develops therapeutics. Her work is credited with identifying an essential role for the thymus in T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. She has conducted numerous early phase and first-in-human and first-in-child clinical trials using numerous immune therapies including one that has been granted Breakthrough Therapy Designation by the FDA. Her group has identified a major feature limiting the activity of an immune therapy called CAR T cells and has developed novel approaches to prevent and reverse this feature. She is the recipient of numerous awards, including the Richard V. Smalley Award highlighting her achievements in immuno-oncology, the AACR-St. Baldrick’s Award for Outstanding Achievement in Pediatric Cancer Research, and the ASCO Pediatric Oncology Award. She is a member of the American Society of Clinical Investigation and is a Fellow of the American Academy of Physicians and the AACR Academy. She serves in numerous national leadership positions, including co-PI on the NCI Pediatric Cancer Immunotherapy Network (U54), and co-Leader of the St. Baldrick’s-StandUp2Cancer Pediatric Dream Team. She is Board Certified in Pediatrics, Pediatric Hematology-Oncology, and Internal Medicine.

The Compassionate Care Award recognizes a patient/nurse navigator (clinical/nurse, community health worker, social worker in the role of a navigator) for his or her outstanding contributions to patient care, support or education. Sarcoma is a challenging disease to navigate alone, and many sarcoma patients need additional support. Navigators assist patients from diagnosis to survivorship, helping them understand their condition and treatments as well as manage side effects; coordinate care among medical specialists; and connect patients to available community resources to overcome barriers to care. They can also help patients manage their psychosocial needs, such as work, school and home environments; relationships; mental and emotional health; and financial concerns. SFA recognizes the important role these individuals play in the sarcoma patient journey.

Devon Ciampa, LCSW-C, OSW-C

Clinical Social Worker, The Johns Hopkins Children’s Center, AYA Patient Navigator for Johns Hopkins through the Ulman Foundation

 

Devon Ciampa, LCSW-C, OSW-C, is a passionate, energetic member of the social work field with a range of program development and clinical experience from both the for-profit and not-for-profit arenas. Ms. Ciampa was nominated for the SFA Compassionate Care Award by the family of Officer Spencer Butler Wiersberg. The family stated, “Devon understood the unique struggles Spencer was facing, both as a cancer patient and as a young adult professional. She tirelessly helped us do the behind-the-scenes work to benefit Spencer so that all he saw was a seamless, united front of people who love him. Devon is one of the blessings we continue to carry with us from the worst time in our lives.”

 

Ms. Ciampa is a clinical social worker in pediatric oncology at The Johns Hopkins Children’s Center and the AYA patient navigator for Johns Hopkins through the Ulman Foundation. Through the Ullman Foundation, she also works with individual AYA patients, participates in NIH research related to improving AYA patient care and is working on building the unit’s first AYA program focused on important periods of transition. She has helped run educational and leadership programs for youth in India and Sri Lanka and, while in China, Ms. Ciampa was also the language learning director of the largest Disney English school with The Walt Disney Company in Shanghai and served in the Peace Corps as a university teacher in Chongqing.

 

Ms. Ciampa has been invited to speak at various events on topics related to the young adult community including the FDA, Leukemia & Lymphoma Society, the World Learning African Exchange on Children in Need and the AIR American/Russian Delegation Exchange on Transitioning Youth.  Ms. Ciampa holds advanced degrees in film production from Boston University as well as in International Educational Policy and Social Work, both from Columbia University. She is currently a doctoral candidate in University of Pennsylvania’s DSW program.

Courage Award honorees illustrate, through their personal efforts and actions, sarcoma advocacy. These individuals are patients, survivors, caregivers, and advocates who inspire others by using their platform on behalf of sarcoma patients and survivors to create hope and a better life for the sarcoma community. Many do not think they have done something special but who have inspired others and are making a difference for sarcoma patients and their families. The Courage Award honors patients who have demonstrated strength and perseverance in their sarcoma diagnosis.

Technoblade

Technoblade, real name: Alexander, was an American YouTuber and internet personality known for his YouTube channel, Technoblade, a Minecraft persona in the guise of a pig that he started at 14 years old. He is widely regarded by the game’s community as one of the best Minecraft players and Minecraft content creators. In the beginning, he plugged away at making videos, attracting a small but steadily growing group of followers with a goal of accumulating 10 million subscribers, an achievement reached by very few*. In July 2021 at the age of 22, after noticing pain in his right arm and a sudden lump, he was diagnosed with sarcoma and chest scans revealed metastasis to both lungs.  Alex endured chemotherapy and radiation treatments, an embolization procedure tumor, and also participated in a clinical trial for the treatment, Milademetan. Throughout his sarcoma journey, he decided to use his significant platform to help support sarcoma research, even if it most likely would not gain results in time for him. His first effort for SFA was “Minecraft But Viewers Control The Game (Charity Event).” Still weak from chemotherapy, he played for almost four hours, raising over $360,000. Throughout his treatment, he continued to do more for research, and made February 2022 his own Sarcoma Awareness Month, raising an additional $150,000.  In total, Technoblade rallied his followers to raise over $1 million for sarcoma research. Unfortunately, tests revealed that his sarcoma had continued to grow and the masses in his lungs had begun pressing against his heart.  He died in June of 2022, shortly after his 23rd birthday, at home, surrounded by his family. The public reaction to the announcement of his death was overwhelming.  And rather than focus on what an amazing gamer he was, or how smart or how funny he was, instead people talked about his kindness and his generosity. People spoke about how much his videos helped them through a difficult time in their lives. Even now, people are still quoting his oft-repeated catchphrases, including, “Technoblade never dies.”

 

*In June 2022, Technoblade’s channel had reached 10.8 million subscribers and in August 2022, it posthumously reached fifteen million subscribers.

Amira Yunis Courage Award honorees illustrate, through their personal efforts and actions, sarcoma advocacy. These individuals are patients, survivors, caregivers, and advocates who inspire others by using their platform on behalf of sarcoma patients and survivors to create hope and a better life for the sarcoma community. Many do not think they have done something special but who have inspired others and are making a difference for sarcoma patients and their families. The Amira Yunis Courage Award honors patients who have demonstrated strength and perseverance in their sarcoma diagnosis.

Todd Barron

Todd Barron, the father of two beautiful young daughters, married to the love of his life, Debra, was forty-three when he was diagnosed with Ewing’s sarcoma in February 2018. Since his initial diagnosis, Todd has undergone two major surgical resections of his lower leg, twenty rounds of chemotherapy, and over forty-five sessions of radiation therapy. He participated in a clinical trial of a promising new treatment for soft tissue sarcomas and eventually had an above the knee amputation of his left leg. Unfortunately, just over a month after his amputation, while he was starting the long and challenging process of learning to walk using a prosthetic leg, he was told the sarcoma had metastasized to his lungs. The news was devastating. At this point, he had exhausted all known cures for Ewing’s sarcoma. Todd started treatment with Votrient knowing it would not be a cure but could potentially extend his life dramatically. The treatment has been successful, and his sarcoma has been relatively under control for the past year. He has had a few small tumors grow during this time, but they have been successfully treated with radiation therapy.

 

Throughout all these treatments, Todd has never stopped working as a financial advisor, volunteering with various charities, and spending quality time on memorable vacations with family and friends. His positive attitude has been inspirational to all who know him. Some might say that Todd is living like he is dying, but if you ask him, he is just living with sarcoma. Always one to go out of his way to help others, Todd now mentors another young father recently diagnosed with Ewing’s sarcoma. He hopes to inspire this friend and other people like him, to enjoy the good things in life while living with this disease. Todd knows there is no cure for his Ewing’s sarcoma yet. He understands that there will likely not be a cure in his lifetime. But he is grateful for the life he is able to live right now, enjoying his large and supportive network of loving family and friends, while his sarcoma is under control, enabling him to live another glorious day.

VIEW OUR PAST AWARD RECIPIENTS


THE SARCOMA FOUNDATION OF AMERICA WOULD LIKE TO THANK OUR GENEROUS SPONSORS

RESEARCH SPONSORS

HOPE SPONSORS

DISCOVERY SPONSORS

INNOVATOR SPONSORS

.

.

.

.

.

.

.

.

.

.

.

.

.

.